Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Sight Sciences (SGHT) over the last 6 years, with Q3 2025 value amounting to $92.4 million.

  • Sight Sciences' Cash & Equivalents fell 2209.02% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.4 million, marking a year-over-year decrease of 2209.02%. This contributed to the annual value of $120.4 million for FY2024, which is 1286.62% down from last year.
  • As of Q3 2025, Sight Sciences' Cash & Equivalents stood at $92.4 million, which was down 2209.02% from $101.5 million recorded in Q2 2025.
  • Sight Sciences' Cash & Equivalents' 5-year high stood at $271.5 million during Q3 2021, with a 5-year trough of $35.6 million in Q2 2021.
  • In the last 5 years, Sight Sciences' Cash & Equivalents had a median value of $141.3 million in 2023 and averaged $155.7 million.
  • In the last 5 years, Sight Sciences' Cash & Equivalents surged by 51873.66% in 2022 and then tumbled by 2986.39% in 2023.
  • Over the past 5 years, Sight Sciences' Cash & Equivalents (Quarter) stood at $260.7 million in 2021, then fell by 29.03% to $185.0 million in 2022, then dropped by 25.34% to $138.1 million in 2023, then dropped by 12.87% to $120.4 million in 2024, then dropped by 23.25% to $92.4 million in 2025.
  • Its Cash & Equivalents stands at $92.4 million for Q3 2025, versus $101.5 million for Q2 2025 and $108.8 million for Q1 2025.